Product Pipeline

R&D Projects	Indications	Status
HY3000 Nasal Spray	Prevention & treatment of COVID-19	Phase III
HY3001 COVID-19 Peptide Vaccine	Prevention of COVID-19	Preclinical
HY3003 GLP-1R/GIPR/GCGR Triple Agonist	Diabetes mellitus & Weight loss & MASH	Preclinical
Glatiramer Acetate Injection	Multiple sclerosis	Approved in US
Cetrorelix Acetate for Injection	Assisted reproduction	Pending approval
Teriparatide Injection	Osteoporosis	Pending approval
Carboprost Tromethamine Injection	Postpartum hemorrhage	Pending approval
Semaglutide Injection	Diabetes mellitus & Weight loss	Phase III
Abaloparatide Injection	Osteoporosis	FDF Process Validation
Teriparatide Acetate for Injection	Osteoporosis	FDF Process Validation
Difelikefalin acetate Injection	CKD-Pruritus	FDF Process Validation
Tirzepatide Injection	Diabetes mellitus & Weight loss	Pending approval
Linaclotide Capsules	IBS-C and CIC	FDF Process Validation
Plecanatide Tablets	IBS-C and CIC	API Process Validation
Etelcalcetide Hydrochloride Injection	CKD-Econdary hyperparathyroidism	API Process Validation
Lanreotide Acetate Sustained-Release Injection	Acromegaly	API Process Validation
Semaglutide Tablets	Diabetes mellitus & Weight loss	API Process Validation
Sucrose Iron Hydroxide Chewable Tablets	CKD-Related hyperphosphatemia	R&D
Ferric Carboxymaltose Injection	Iron deficiency anemia	R&D
Pegcetacoplan Injection	Geographic atrophy	R&D
Carbetocin injection	Prevention of postpartum haemorrhage	Approved in Indonesia

Remark：Singapore（SGP ）; Saudi Arabia（KSA ）; Jordan（JOR ）; Russia（RUS）; Columbia（COL ）; New Zealand（NZL）; Mexico（MEX）; Macedonia（MKD）; Bangladesh（BGD）; Israel（ISR）；Vietnam（VNM）；Canada（CAN）

Products

Difelikefalin

Elamipretide

Etelcalcetide

Exenatide

Glucagon

Lanreotide

Leuprorelin

Motixafortide

Product Pipeline